Journal of Clinical Oncology, Vol 16, 3774-3781, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia

J Ciudad, JF San Miguel, MC Lopez-Berges, B Vidriales, B Valverde, M Ocqueteau, G Mateos, MD Caballero, J Hernandez, MJ Moro, MV Mateos and A Orfao
Servicio de Hematologia Hospital Clinico Universitario, Universidad de Salamanca, Spain.

PURPOSE: The identification of immunophenotypic aberrancies through multiparametric flow cytometry makes the differentiation between normal and leukemic cells relatively simple and quick, and is therefore an attractive method for the investigation of minimal residual disease (MRD). In this report, we have analyzed the impact on relapse and relapse-free survival (RFS) of detecting immunophenotypical aberrant cells in acute lymphoblastic leukemia (ALL) patients in cytomorphologic complete remission (CR). MATERIALS AND METHODS: Two hundred eleven bone marrow (BM) samples from 53 consecutive ALL (37 precursor B-ALL and 16 T-ALL) patients were analyzed. The only selection criteria were to have at least one aberrant immunophenotypic feature at diagosis and to have achieved cytomorphologic CR after induction therapy. For MRD detection, all follow-up samples were analyzed with triple labelings using a two- step acquisition procedure, in which 106 cells were screened for the possible persistence of residual leukemic cells with the same phenotypic aberrancy as that identified diagnosis. RESULTS: Patients who displayed a gradual increase in MRD levels showed a higher relapse rate (90% v22%; P < .00001) and shorter median RFS (12 months v not reached; P < .0001) than those with stable or decreasing MRD levels. This adverse prognostic influence also was observed when children and adults, as well as B-ALL and T-ALL patients, were analyzed separately. An MRD level > or = or greater than 10(-3) discriminated two risk groups of ALL patients with significantly different relapse rates and RFS at all treatment phases (end of induction, consolidation, maintenance, and out of treatment). CONCLUSION: Multiparametric flow cytometry of MRD in ALL patients is a valuable tool for relapse prediction and for the identification of a cohort of patients with very poor prognosis.

This article has been cited by other articles:

				A. Al-Mawali, D. Gillis, and I. Lewis The Role of Multiparameter Flow Cytometry for Detection of Minimal Residual Disease in Acute Myeloid Leukemia Am J Clin Pathol, January 1, 2009; 131(1): 16 - 26. [Abstract] [Full Text] [PDF]

				M. J. Borowitz, M. Devidas, S. P. Hunger, W. P. Bowman, A. J. Carroll, W. L. Carroll, S. Linda, P. L. Martin, D. J. Pullen, D. Viswanatha, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study Blood, June 15, 2008; 111(12): 5477 - 5485. [Abstract] [Full Text] [PDF]

				W. Janni, B. Rack, K. Lindemann, and N. Harbeck Detection of Micrometastatic Disease in Bone Marrow: Is It Ready for Prime Time? Oncologist, August 1, 2005; 10(7): 480 - 492. [Abstract] [Full Text] [PDF]

				M. Stanulla, E. Schaeffeler, T. Flohr, G. Cario, A. Schrauder, M. Zimmermann, K. Welte, W.-D. Ludwig, C. R. Bartram, U. M. Zanger, et al. Thiopurine Methyltransferase (TPMT) Genotype and Early Treatment Response to Mercaptopurine in Childhood Acute Lymphoblastic Leukemia JAMA, March 23, 2005; 293(12): 1485 - 1489. [Abstract] [Full Text] [PDF]

				M.-B. Vidriales, J. J. Perez, M. C. Lopez-Berges, N. Gutierrez, J. Ciudad, P. Lucio, L. Vazquez, R. Garcia-Sanz, M. C. del Canizo, J. Fernandez-Calvo, et al. Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value Blood, June 15, 2003; 101(12): 4695 - 4700. [Abstract] [Full Text] [PDF]

				E. Coustan-Smith, J. Sancho, M. L. Hancock, B. I. Razzouk, R. C. Ribeiro, G. K. Rivera, J. E. Rubnitz, J. T. Sandlund, C.-H. Pui, and D. Campana Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia Blood, September 18, 2002; 100(7): 2399 - 2402. [Abstract] [Full Text] [PDF]

				M. N. Dworzak, G. Froschl, D. Printz, G. Mann, U. Potschger, N. Muhlegger, G. Fritsch, and H. Gadner Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia Blood, March 15, 2002; 99(6): 1952 - 1958. [Abstract] [Full Text] [PDF]

				J. F. San Miguel, M. B. Vidriales, C. Lopez-Berges, J. Diaz-Mediavilla, N. Gutierrez, C. Canizo, F. Ramos, M. J. Calmuntia, J. J. Perez, M. Gonzalez, et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification Blood, September 15, 2001; 98(6): 1746 - 1751. [Abstract] [Full Text] [PDF]

				J.-S. Chen, E. Coustan-Smith, T. Suzuki, G. A. Neale, K. Mihara, C.-H. Pui, and D. Campana Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia Blood, April 1, 2001; 97(7): 2115 - 2120. [Abstract] [Full Text] [PDF]

				E. Coustan-Smith, J. Sancho, M. L. Hancock, J. M. Boyett, F. G. Behm, S. C. Raimondi, J. T. Sandlund, G. K. Rivera, J. E. Rubnitz, R. C. Ribeiro, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia Blood, October 15, 2000; 96(8): 2691 - 2696. [Abstract] [Full Text] [PDF]

				A. Orfao, G. Schmitz, B. Brando, A. Ruiz-Arguelles, G. Basso, R. Braylan, G. Rothe, F. Lacombe, F. Lanza, S. Papa, et al. Clinically Useful Information Provided by the Flow Cytometric Immunophenotyping of Hematological Malignancies: Current Status and Future Directions Clin. Chem., October 1, 1999; 45(10): 1708 - 1717. [Abstract] [Full Text] [PDF]

				K. Pantel, R. J. Cote, and O. Fodstad Detection and Clinical Importance of Micrometastatic Disease J Natl Cancer Inst, July 7, 1999; 91(13): 1113 - 1124. [Abstract] [Full Text] [PDF]